NCT01326143

Brief Summary

The purpose of this study is to evaluate the long-term efficacy, tolerance and compliance of ORM Narval Mandibular Repositioning Device (MRD) as a second-line treatment for patients with severe Obstructive Sleep Apnea Hypopnea (OSAH) syndrome who refuse or are intolerant to Continuous Positive Airway Pressure (CPAP) treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
360

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2011

Longer than P75 for all trials

Geographic Reach
1 country

26 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 29, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 30, 2011

Completed
1 month until next milestone

Study Start

First participant enrolled

May 1, 2011

Completed
7.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2019

Completed
26 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 27, 2019

Completed
Last Updated

April 2, 2020

Status Verified

March 1, 2020

Enrollment Period

7.8 years

First QC Date

March 29, 2011

Last Update Submit

March 31, 2020

Conditions

Keywords

MRDNarvalOral applianceObstructive Sleep apneaOSAHOSA treatment

Outcome Measures

Primary Outcomes (1)

  • Percentage of patients with Apnea/Hypopnea Index (AHI) reduced by at least 50% compared to baseline measured by Polygraphy/Polysomnography (PG/PSG)

    5 years

Secondary Outcomes (6)

  • Percentage of patients with AHI reduced by at least 50% compared to baseline measured by PG/PSG

    3 months and 2 years

  • Percentage of patients who no longer suffer from severe daytime sleepiness (Epworth Sleepiness scale)

    3 months, 2 years and 5 years

  • Sleep quality of life (Quebec Sleep Questionaire)

    3 months, 2 years and 5 years

  • Percentage of patients who stopped the therapy for dento-maxillofacial side effects

    6 months, 1, 2, 3, 4 and 5 years

  • Percentage of patients with satisfactory compliance

    3 months, 2 and 5 years.

  • +1 more secondary outcomes

Study Arms (1)

ORM Narval MRD

Device: ORM Narval MRD

Interventions

ORM Narval MRD

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Severe Obstructive Sleep Apnea Hypopnea

You may qualify if:

  • Adult patient with severe OSAH (AHI \> 30 or AHI of between 5 and 30 along with severe daytime sleepiness),
  • intolerant to or having refused CPAP therapy,
  • no dental, parodontal or articulatory contraindications,
  • no experience of any mandibular advancement device therapy,
  • medical insurance.

You may not qualify if:

  • severe psychiatric disorders or severe neuromuscular disorders
  • \> 20% of central apneas during the baseline assessment,
  • severe OSAH with an AHI \> 30 associated with another sleep pathology (narcolepsy with or without cataplexy, idiopathic hypersomnia, severe restless legs syndrome),
  • pregnant or breastfeeding woman,
  • Informed consent not signed,
  • patient requiring special protection such as patients with appointed guardians and patients without legal or administrative rights,
  • patient who is completely or partially edentulous

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (26)

Fondation Bon Sauveur / cabinet médical / cabinet dentaire

Albi, France

Location

CH Antibes / cabinet dentaire

Antibes, France

Location

CH Béziers

Béziers, France

Location

CHU Avicennes

Bobigny, France

Location

Polyclinique du Tondu / cabinet dentaire

Bordeaux, France

Location

CHG Chalon en Champagne

Châlons-en-Champagne, France

Location

CH Compiègne Senlis / cabinets dentaires

Compiègne, France

Location

CHU Grenoble

Grenoble, France

Location

Cabinet médical / cabinet dentaire

Lagny, France

Location

CHRU Lille

Lille, France

Location

Cabinet médical Lyon

Lyon, France

Location

CHU La Timone / cabinet médical

Marseille, France

Location

CHRU Montpellier / Clinique Beau Soleil / Faculté d'Odontologie / cabinet dentaire

Montpellier, France

Location

CH Montreuil

Montreuil, France

Location

Centre Médical Plateau de Haye / cabinet médical / cabinet dentaire

Nancy, France

Location

Maison de la Mutualité / polyclinique de l'Atlantique

Nantes, France

Location

Cabinet médical / cabinet dentaire

Nice, France

Location

Hôpital Bichat Claude Bernard

Paris, France

Location

Hôpital Pitié Salpetriere

Paris, France

Location

Hôtel Dieu

Paris, France

Location

CHU Poitiers

Poitiers, France

Location

CHRU Rennes / polyclinique St Laurent / cabinet dentaire

Rennes, France

Location

CHRU Rouen

Rouen, France

Location

CHU Toulouse

Toulouse, France

Location

Clinique de l'Union

Toulouse, France

Location

CH Valence

Valence, France

Location

Related Publications (3)

  • Vecchierini MF, Attali V, Collet JM, d'Ortho MP, El Chater P, Kerbrat JB, Leger D, Monaca C, Monteyrol PJ, Morin L, Mullens E, Pigearias B, Meurice JC; ORCADES investigators. A custom-made mandibular repositioning device for obstructive sleep apnoea-hypopnoea syndrome: the ORCADES study. Sleep Med. 2016 Mar;19:131-40. doi: 10.1016/j.sleep.2015.05.020. Epub 2015 Jun 29.

  • Attali V, Vecchierini MF, Collet JM, d'Ortho MP, Goutorbe F, Kerbrat JB, Leger D, Lavergne F, Monaca C, Monteyrol PJ, Morin L, Mullens E, Pigearias B, Martin F, Tordjman F, Khemliche H, Lerousseau L, Meurice JC; ORCADES investigators. Efficacy and tolerability of a custom-made Narval mandibular repositioning device for the treatment of obstructive sleep apnea: ORCADES study 2-year follow-up data. Sleep Med. 2019 Nov;63:64-74. doi: 10.1016/j.sleep.2019.04.021. Epub 2019 Jun 12.

  • Vecchierini MF, Attali V, Collet JM, d'Ortho MP, Goutorbe F, Kerbrat JB, Leger D, Lavergne F, Monaca C, Monteyrol PJ, Morin L, Mullens E, Pigearias B, Martin F, Khemliche H, Lerousseau L, Meurice JC; ORCADES investigators; Abedipour D, Allard-Redon A, Aranda A, Attali V, Bavozet F, Becu M, Beruben W, Bessard J, Bonafe I, Boukhana M, Chabrol B, Chatte G, Lebret C, Collet JM, Coste O, Dumont N, Durand-Amat S, D'ortho MP, Elbaum JM, De Santerre OG, Goutorbes F, Grandjean T, Guyot W, Hammer D, Havasi C, Huet P, Kerbrat JB, Khemliche H, Koltes C, Leger D, Lacassagne L, Laur X, Lerousseau L, Liard O, Loisel C, Longuet M, Mallart A, Martin F, Merle Beral F, Meurice JC, Mokhtari Z, Monaca C, Monteyrol PJ, Muir JF, Mullens E, Muller D, Paoli C, Petit FX, Pigearias B, Pradines M, Prigent A, Putterman G, Rey M, Samama M, Tamisier R, Tiberge M, Tison C, Tordjman F, Triolet B, Vacher C, Vecchierini MF, Verain A. Sex differences in mandibular repositioning device therapy effectiveness in patients with obstructive sleep apnea syndrome. Sleep Breath. 2019 Sep;23(3):837-848. doi: 10.1007/s11325-018-1766-8. Epub 2018 Dec 22.

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Officials

  • Marie-Françoise VECCHIERINI-BLINEAU, Dr

    Hôtel Dieu, Paris

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 29, 2011

First Posted

March 30, 2011

Study Start

May 1, 2011

Primary Completion

February 1, 2019

Study Completion

February 27, 2019

Last Updated

April 2, 2020

Record last verified: 2020-03

Locations